BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Peroukides S, Makatsoris T, Koutras A, Tsamandas A, Onyenadum A, Labropoulou-Karatza C, Kalofonos H. Lapatinib-induced hepatitis: A case report. World J Gastroenterol 2011; 17(18): 2349-2352 [PMID: 21633602 DOI: 10.3748/wjg.v17.i18.2349]
URL: https://www.wjgnet.com/1007-9327/full/v17/i18/2349.htm
Number Citing Articles
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle, Rina Patel. Oncologic Critical Care2019; : 1 doi: 10.1007/978-3-319-74698-2_21-1
Debra H. Josephs, Danielle S. Fisher, James Spicer, Robert J. Flanagan. Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsTherapeutic Drug Monitoring 2013; 35(5): 562 doi: 10.1097/FTD.0b013e318292b931
F. Alessandrino, S.H. Tirumani, K.M. Krajewski, A.B. Shinagare, J.P. Jagannathan, N.H. Ramaiya, D.N. Di Salvo. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitorsClinical Radiology 2017; 72(7): 521 doi: 10.1016/j.crad.2017.04.003
Stephanie A. Howard, Michael H. Rosenthal, Jyothi P. Jagannathan, Katherine M. Krajewski, Atul B. Shinagare, Nikhil H. Ramaiya, Sree Harsha Tirumani. Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in OncologyAmerican Journal of Roentgenology 2015; 204(5): 919 doi: 10.2214/AJR.14.12876
Nelia Hernandez. Hepatotoxicity of New Antitumor AgentsCurrent Hepatology Reports 2017; 16(4): 293 doi: 10.1007/s11901-017-0381-7
Y. Maor, S. Malnick. Liver Injury Induced by Anticancer Chemotherapy and Radiation TherapyInternational Journal of Hepatology 2013; 2013: 1 doi: 10.1155/2013/815105
Haochen Jiang, Ying Jin, Hao Yan, Zhifei Xu, Bo Yang, Qiaojun He, Peihua Luo. Hepatotoxicity of FDA-approved small molecule kinase inhibitorsExpert Opinion on Drug Safety 2021; 20(3): 335 doi: 10.1080/14740338.2021.1867104
Joanna E. Barbara, Faraz Kazmi, Andrew Parkinson, David B. Buckley. Metabolism-Dependent Inhibition of CYP3A4 by Lapatinib: Evidence for Formation of a Metabolic Intermediate Complex with a Nitroso/Oxime Metabolite Formed via a Nitrone IntermediateDrug Metabolism and Disposition 2013; 41(5): 1012 doi: 10.1124/dmd.113.051151
Lishan Lin, Cen Xie, Zhiwei Gao, Xiaoyan Chen, Dafang Zhong. Metabolism and Pharmacokinetics of Allitinib in Cancer Patients: The Roles of Cytochrome P450s and Epoxide Hydrolase in its BiotransformationDrug Metabolism and Disposition 2014; 42(5): 872 doi: 10.1124/dmd.113.056341
David E. Kleiner. Macsween's Pathology of the Liver2018; : 673 doi: 10.1016/B978-0-7020-6697-9.00012-1
Noëmi Johanna Roos, Diell Aliu, Jamal Bouitbir, Stephan Krähenbühl. Lapatinib Activates the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 Pathway in HepG2 CellsFrontiers in Pharmacology 2020; 11 doi: 10.3389/fphar.2020.00944
Camille Houron, Marie Danielou, Olivier Mir, Bernard Fromenty, Gabriel Perlemuter, Cosmin Sebastian Voican. Multikinase inhibitor-induced liver injury in patients with cancer: A review for cliniciansCritical Reviews in Oncology/Hematology 2021; 157: 103127 doi: 10.1016/j.critrevonc.2020.103127
Neil M. Iyengar, Monica N. Fornier, Steven M. Sugarman, Maria Theodoulou, Tiffany A. Troso-Sandoval, Gabriella M. D'Andrea, Pamela R. Drullinsky, Devika Gajria, Shari B. Goldfarb, Elizabeth A. Comen, Diana E. Lake, Shanu Modi, Tiffany A. Traina, Mario E. Lacouture, Melanie F. Chen, Sujata Patil, José Baselga, Larry Norton, Clifford A. Hudis, Chau T. Dang. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast CancerClinical Breast Cancer 2016; 16(2): 87 doi: 10.1016/j.clbc.2015.09.009
Zhuo Zhang, Ling Xu, Naishan Qin, Jixin Zhang, Qian Xiang, Qian Liu, Yuanjia Cheng, Yuge Bai, Qianxin Liu, Yinhua Liu, Xuening Duan, Yimin Cui. Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patientThoracic Cancer 2021; 12(12): 1912 doi: 10.1111/1759-7714.13986
Jaymin J. Kathiriya, Ravi Ramesh Pathak, Eric Clayman, Bin Xue, Vladimir N. Uversky, Vrushank Davé. Presence and utility of intrinsically disordered regions in kinasesMol. BioSyst. 2014; 10(11): 2876 doi: 10.1039/C4MB00224E
Chalermrat Bunchorntavakul, K. Rajender Reddy. Drug HepatotoxicityClinics in Liver Disease 2017; 21(1): 115 doi: 10.1016/j.cld.2016.08.009
Jennifer E. Bissada, Vivian Truong, Arsany A. Abouda, Kahari J. Wines, Rachel D. Crouch, Klarissa D. Jackson. Interindividual Variation in CYP3A Activity Influences Lapatinib BioactivationDrug Metabolism and Disposition 2019; 47(11): 1257 doi: 10.1124/dmd.119.088823
Wimonchat Tangamornsuksan, Chuenjid Kongkaew, C. N. Scholfield, Suphat Subongkot, Manupat Lohitnavy. HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysisThe Pharmacogenomics Journal 2020; 20(1): 47 doi: 10.1038/s41397-019-0092-2
JL Woodhead, K Yang, KLR Brouwer, SQ Siler, SH Stahl, JL Ambroso, D Baker, PB Watkins, BA Howell. Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILICPT: Pharmacometrics & Systems Pharmacology 2014; 3(7): 123 doi: 10.1038/psp.2014.21
Kirsty Wai-Chung Lee, Stephen Lam Chan. Hepatotoxicity of targeted therapy for cancerExpert Opinion on Drug Metabolism & Toxicology 2016; 12(7): 789 doi: 10.1080/17425255.2016.1190831
Melvin J. Rivera, Bryan Do, Jeffrey C. Bryan, Terri Lynn Shigle, Rina Patel. Oncologic Critical Care2020; : 201 doi: 10.1007/978-3-319-74588-6_21